Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHReported by Nathan Reiff. Article Published: 2/12/2026. 
Article Highlights - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a key window into a firm's pipeline and development progress. Even well-established, steady firms can surprise with growth after the release of a new blockbuster drug or medical device, and earnings periods give management a chance to provide context beyond what investors might learn from FDA approval notices. When healthcare companies release earnings reports on the same day, investors can face a busy stretch of news and trading decisions. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are the highlights and takeaways for healthcare investors planning around those updates. AstraZeneca Firms Up Cancer Business in a Strong Quarterly Performance The Wall Street Journal is asking whether a stock market crash is coming. Research from Weiss Ratings suggests the first half of 2026 could be very tough for certain stocks as a radical shift hits the market. Some of America's most popular names could take serious damage. Analysts have identified five stocks you should consider avoiding before this event plays out. If these are in your portfolio, you'll want to review your positions carefully. See the five stocks to avoid and learn what's driving this shift. U.K.-based AstraZeneca closed out 2025 by cementing its position as a leading provider of cancer medicines, which made up roughly 44% of product sales in the final quarter. Sales of oncology drugs such as Imfinzi and Enhertu rose as much as 48% year over year (YOY), helping to propel total revenue up 8.6% to $58.7 billion for the quarter. After-tax profits climbed with revenue, rising to $10.2 billion from $7.0 billion in the prior-year quarter. The company's board declared a second interim dividend that is 7 cents higher than last year's payment. Investors have more potential catalysts ahead as AstraZeneca advances dozens of drug candidates through trials. Management said 20 Phase 3 readouts are expected in 2026, and the firm forecasted solid increases to both total revenue and core earnings per share (EPS) for the full year. In the hours after the company released its strong earnings report, AZN shares rose about 3%. While 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street questions the firm's valuation—consensus price targets imply shares could fall roughly 51% relative to current levels, based on a $95.75 target. TAVR Momentum Fuels Edwards Sales Growth, Though Margins and EPS Show Limits Edwards makes replacement heart valves and related surgical devices, along with monitoring systems. The firm's Q4 2025 results were broadly positive: sales grew 13.3% YOY, driven by strong transcatheter aortic valve replacement (TAVR) demand and uptake of the latest SAPIEN valve. However, adjusted EPS missed analyst estimates, and gross profit margin fell 0.8% YOY, tempering some of the headline strength. Despite the mixed signals, Edwards reiterated confidence in its 2026 outlook, which calls for sales growth of 8%–10% YOY and EPS between $2.90 and $3.05. EW shares rose above $80 in after-hours trading, up about 4% from the previous close. About two-thirds of analysts who cover EW rate the shares a Buy, and Wall Street's consensus target suggests roughly 25% upside to $96.77. Orthopedic Demand Remains Strong, but Zimmer Faces Some Headwinds Zimmer Biomet, a maker of joint and bone replacement systems and implants, saw its shares climb more than 3% after reporting EPS of $2.42, $0.04 above consensus, and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of estimates. Persistent demand for orthopedic products supported both top- and bottom-line growth. Zimmer is also refocusing its business toward the U.S., which represents close to 60% of sales. With insured patient utilization continuing to rise, demand for Zimmer's products is expected to remain elevated in the near term. That said, the company faces headwinds from tariffs and other cost pressures that could weigh on EPS and revenue in 2026. Management delivered conservative guidance in the latest earnings report, including adjusted EPS of $8.30–$8.45 and projected free cash flow improvement of 8%–10%. Prior to the release, analysts were divided on Zimmer; the stock carried an overall Hold rating, despite about 15% projected upside potential. Analyst views remain mixed.
| 
